BG105362A - NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION - Google Patents

NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION

Info

Publication number: BG105362A
Authority: BG; Bulgaria
Prior art keywords: preparation; methods; intermediates; peptide gnrh; gnrh agents
Prior art date: 1998-08-20

Application number

BG105362A

Other languages

Bulgarian (bg)

English (en)

Inventor

Mark Anderson

Haresh VAZIR

David LUTHIN

Genevieve PADERES

Ved PATHAK

Lance CHRISTIE

Yufeng Hong

Eileen Tompkins

Haitao Li

James Faust

Original Assignee

Agouron Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-20

Filing date

2001-03-19

Publication date

2001-12-31

2001-03-19 Application filed by Agouron Pharmaceuticals, Inc. filed Critical Agouron Pharmaceuticals, Inc.

2001-12-31 Publication of BG105362A publication Critical patent/BG105362A/xx

Links

101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 title abstract 3
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 title abstract 2
239000000543 intermediate Substances 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract 1
102000006771 Gonadotropins Human genes 0.000 abstract 1
108010086677 Gonadotropins Proteins 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000035558 fertility Effects 0.000 abstract 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 1
239000002622 gonadotropin Substances 0.000 abstract 1
229940035638 gonadotropin-releasing hormone Drugs 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
239000002207 metabolite Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
230000001105 regulatory effect Effects 0.000 abstract 1
230000001850 reproductive effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000003270 steroid hormone Substances 0.000 abstract 1
230000001629 suppression Effects 0.000 abstract 1
230000002194 synthesizing effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BG105362A 1998-08-20 2001-03-19 NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION BG105362A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9752098P	1998-08-20	1998-08-20
PCT/US1999/018790 WO2000020358A2 (en)	1998-08-20	1999-08-20	NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION

Publications (1)

Publication Number	Publication Date
BG105362A true BG105362A (en)	2001-12-31

Family

ID=22263796

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG105362A BG105362A (en)	1998-08-20	2001-03-19	NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION

Country Status (33)

Country	Link
EP (1)	EP1105120B1 (de)
JP (1)	JP2002535244A (de)
KR (1)	KR20010085402A (de)
CN (1)	CN1379666A (de)
AP (1)	AP2001002053A0 (de)
AT (1)	ATE291423T1 (de)
AU (1)	AU759310B2 (de)
BG (1)	BG105362A (de)
BR (1)	BR9913374A (de)
CA (1)	CA2341346A1 (de)
CZ (1)	CZ2001523A3 (de)
DE (1)	DE69924387D1 (de)
EA (1)	EA200100255A1 (de)
EE (1)	EE200100102A (de)
ES (1)	ES2237966T3 (de)
GE (1)	GEP20043315B (de)
HR (1)	HRP20010206A2 (de)
HU (1)	HUP0103622A3 (de)
ID (1)	ID29244A (de)
IL (1)	IL141396A0 (de)
IS (1)	IS5846A (de)
LT (1)	LT4904B (de)
LV (1)	LV12732B (de)
NO (1)	NO20010309L (de)
NZ (1)	NZ509252A (de)
OA (1)	OA11599A (de)
PL (1)	PL356984A1 (de)
SI (1)	SI20746A (de)
SK (1)	SK2262001A3 (de)
TR (1)	TR200100631T2 (de)
WO (1)	WO2000020358A2 (de)
YU (1)	YU13701A (de)
ZA (1)	ZA200100831B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE195716T1 (de) *	1992-04-22	2000-09-15	Ligand Pharm Inc	Retinoid-x rezeptor selektive verbindungen
AP1654A (en) *	1999-03-24	2006-09-01	Anormed Inc	Chemokine receptor binding heterocyclic compounds.
CO5370679A1 (es) *	1999-06-01	2004-02-27	Smithkline Beecham Corp	Inhibidores fab 1
TWI243164B (en)	2001-02-13	2005-11-11	Aventis Pharma Gmbh	Acylated indanyl amines and their use as pharmaceuticals
AU2002312348A1 (en) *	2001-06-06	2002-12-16	Agouron Pharmaceuticals, Inc.	Non-peptide gnrh agents, pharmaceutical compositions and methods for their uses, and processes for preparing them
US6881741B2 (en) *	2001-06-11	2005-04-19	Virochem Pharma Inc.	Compounds and methods for the treatment or prevention of Flavivirus infections
US7132438B2 (en)	2001-10-09	2006-11-07	Amgen Inc.	Benzimidazole derivatives
GB0126292D0 (en) *	2001-11-01	2002-01-02	Smithkline Beecham Plc	Compounds
JP2005170790A (ja) *	2002-01-09	2005-06-30	Ajinomoto Co Inc	Ｎ−アルキルスルフォニル置換アミド誘導体
US6521395B1 (en) *	2002-01-30	2003-02-18	Eastman Kodak Company	Infrared couplers for incorporating and recovering metadata
WO2003068769A1 (en) *	2002-02-12	2003-08-21	Pfizer Inc.	Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
TW200304820A (en) *	2002-03-25	2003-10-16	Avanir Pharmaceuticals	Use of benzimidazole analogs in the treatment of cell proliferation
CA2489252A1 (en)	2002-06-13	2003-12-24	Pfizer Inc.	Non-peptide gnrh agents, pharmaceutical compositions and methods for their use
AU2003283607A1 (en) *	2002-11-20	2004-06-15	Amedis Pharmaceuticals Ltd.	Heterocyclic silicon compounds and their use in the treatment of diseases or conditions associated with gnrh (gonadotropin-releasing hormone)
CN100451004C (zh) *	2003-03-31	2009-01-14	大正制药株式会社	嘧啶衍生物
US20050197350A1 (en) *	2003-03-31	2005-09-08	Taisho Pharmaceutical Co., Ltd.	Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
US7427683B2 (en) *	2003-04-25	2008-09-23	Ortho-Mcneil Pharmaceutical, Inc.	c-fms kinase inhibitors
MXPA05011503A (es) *	2003-04-25	2006-05-31	Johnson & Johnson	Inhibidores de la c-fms cinasa.
EP1628661A2 (de) *	2003-06-05	2006-03-01	Vertex Pharmaceuticals Incorporated	Vr1-rezeptor-modulatoren
CA2531512A1 (en) *	2003-07-09	2005-01-20	Paradigm Therapeutics Ltd.	Organosilicon compounds and their use
RU2303594C2 (ru) *	2003-07-09	2007-07-27	Пэредайм Терапьютикс Лтд.	Кремнийорганические соединения и их применение
KR20060033904A (ko) *	2003-07-10	2006-04-20	패러다임 테라퓨틱스 리미티드	규소 화합물과 그 용도
WO2005039564A1 (en) *	2003-10-02	2005-05-06	Vertex Pharmaceuticals Incorporated	Phthalimide compounds useful as protein kinase inhibitors
US20090291915A1 (en) *	2004-12-17	2009-11-26	Graham Andrew Showell	Silicon Compounds and Their Use
WO2006119646A1 (en)	2005-05-13	2006-11-16	Virochem Pharma Inc.	Compounds and methods for the treatment or prevention of flavivirus infections
NZ564222A (en)	2005-06-14	2011-10-28	Taigen Biotechnology Co Ltd	Pyrimidine compounds
US8193206B2 (en)	2005-06-14	2012-06-05	Taigen Biotechnology Co., Ltd.	Pyrimidine compounds
WO2007000582A1 (en) *	2005-06-28	2007-01-04	Takeda Cambridge Limited	Heterocyclic non-peptide gnrh antagonists
DK1910384T3 (da) *	2005-08-04	2012-12-17	Sirtris Pharmaceuticals Inc	Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser
CA2644910C (en)	2006-03-31	2014-01-28	Abbott Laboratories	Indazole compounds
US20080070987A1 (en) *	2006-05-12	2008-03-20	Francesc Yraola Font	Meta-xylylenediamine vanadate salts
CL2008001822A1 (es)	2007-06-20	2009-03-13	Sirtris Pharmaceuticals Inc	Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
AU2008310660A1 (en) *	2007-10-11	2009-04-16	Vertex Pharmaceuticals Incorporated	Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
CN101888991A (zh) *	2007-10-31	2010-11-17	财团法人乙卯研究所	类视色素前体药物化合物
DK2268635T3 (en)	2008-04-21	2015-09-14	Taigen Biotechnology Co Ltd	Heterocyclic Compounds
UY31984A (es) *	2008-07-16	2010-02-26	Boehringer Ingelheim Int	DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas.
US9023834B2 (en)	2008-11-13	2015-05-05	Taigen Biotechnology Co., Ltd.	Lyophilization formulation
SG10201505997TA (en)	2010-08-05	2015-09-29	Amgen Inc	Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase
CN102050823A (zh) *	2010-10-27	2011-05-11	华东理工大学	新型光稳定剂-鸟嘌呤类似物的合成及表征
US9199918B2 (en) *	2011-02-15	2015-12-01	Georgetown University	Small molecule inhibitors of AGBL2
CN103781763B (zh)	2011-05-16	2017-03-22	生态学有限公司	作为钾通道阻断剂的胺衍生物
MY169319A (en)	2011-07-26	2019-03-21	Sanofi Sa	3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
WO2013067578A1 (en) *	2011-11-07	2013-05-16	The University Of Queensland	Modulators of c3a receptors
JP2016504270A (ja) *	2012-10-17	2016-02-12	ザユニバーシティオブブリストル	眼血管形成（ｏｃｕｌａｒｎｅｏｖａｓｃｕｌａｎ）を治療するのに有用な化合物
GB201300304D0 (en) *	2013-01-08	2013-02-20	Kalvista Pharmaceuticals Ltd	Benzylamine derivatives
WO2017070235A1 (en) *	2015-10-19	2017-04-27	Attenua, Inc.	Antitussive compositions and methods
WO2019043217A1 (en)	2017-09-04	2019-03-07	F. Hoffmann-La Roche Ag	DIHYDROBENZIMIDAZOLONES
ES2995214T3 (en)	2019-03-06	2025-02-07	C4 Therapeutics Inc	Heterocyclic compounds for medical treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3499002A (en) *	1968-06-20	1970-03-03	Robins Co Inc A H	1-carbamoyl-3-aroylpyrrolidines
NL6913261A (de) *	1968-09-09	1970-03-11
US3932444A (en) *	1972-04-28	1976-01-13	E. I. Du Pont De Nemours & Co.	4-Imidazolylsulfonylimidazoles
US4013647A (en) *	1976-03-23	1977-03-22	American Home Products Corporation	Morpholine containing tetrazole-5-carboxamide derivatives
GB1491776A (en) *	1976-09-08	1977-11-16	Pfizer Ltd	Thiadiazoles
US4096153A (en) *	1977-01-21	1978-06-20	American Home Products Corporation	Arylene-bis-tetrazole-5-carboxamides
US5236928A (en) *	1991-03-19	1993-08-17	Merck & Co., Inc.	Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists
JPH06509075A (ja)	1991-07-01	1994-10-13	ユニヴァーシティ　テクノロジーズ　インターナショナル　インコーポレイテッド	ＧｎＲＨ及び他の生物学的に活性なリガンドの非感度低下性類縁体
EP0619814A1 (de) *	1991-12-31	1994-10-19	Fujisawa Pharmaceutical Co., Ltd.	Oxadiazolderivate mit acetycholinesterase-hemmender und muscarin-agonistischer wirkung
EP0761654B1 (de) *	1995-08-24	2003-06-18	Basf Aktiengesellschaft	Isoxazole- und Isothiazole-5-carboxamid Derivate, deren Herstellung und deren Verwendung als Herbizide
JP3092946B2 (ja) *	1995-12-14	2000-09-25	メルクエンドカンパニーインコーポレーテッド	ゴナドトロピン放出ホルモン拮抗剤
AU710926B2 (en) *	1996-05-20	1999-09-30	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
US5878393A (en) *	1996-09-09	1999-03-02	Matsushita Electric Industrial Co., Ltd.	High quality concatenative reading system

1999
- 1999-08-20 HU HU0103622A patent/HUP0103622A3/hu unknown
- 1999-08-20 AP APAP/P/2001/002053A patent/AP2001002053A0/en unknown
- 1999-08-20 TR TR2001/00631T patent/TR200100631T2/xx unknown
- 1999-08-20 ID IDW20010406A patent/ID29244A/id unknown
- 1999-08-20 ES ES99968010T patent/ES2237966T3/es not_active Expired - Lifetime
- 1999-08-20 IL IL14139699A patent/IL141396A0/xx unknown
- 1999-08-20 EE EEP200100102A patent/EE200100102A/xx unknown
- 1999-08-20 GE GE4368A patent/GEP20043315B/en unknown
- 1999-08-20 OA OA1200100043A patent/OA11599A/en unknown
- 1999-08-20 SI SI9920076A patent/SI20746A/sl not_active IP Right Cessation
- 1999-08-20 BR BR9913374-1A patent/BR9913374A/pt not_active IP Right Cessation
- 1999-08-20 AT AT99968010T patent/ATE291423T1/de not_active IP Right Cessation
- 1999-08-20 DE DE69924387T patent/DE69924387D1/de not_active Expired - Fee Related
- 1999-08-20 EP EP99968010A patent/EP1105120B1/de not_active Expired - Lifetime
- 1999-08-20 NZ NZ509252A patent/NZ509252A/en unknown
- 1999-08-20 AU AU24709/00A patent/AU759310B2/en not_active Ceased
- 1999-08-20 JP JP2000574479A patent/JP2002535244A/ja active Pending
- 1999-08-20 CA CA002341346A patent/CA2341346A1/en not_active Abandoned
- 1999-08-20 YU YU13701A patent/YU13701A/sh unknown
- 1999-08-20 CZ CZ2001523A patent/CZ2001523A3/cs unknown
- 1999-08-20 EA EA200100255A patent/EA200100255A1/ru unknown
- 1999-08-20 SK SK226-2001A patent/SK2262001A3/sk unknown
- 1999-08-20 WO PCT/US1999/018790 patent/WO2000020358A2/en not_active Ceased
- 1999-08-20 CN CN99812285A patent/CN1379666A/zh active Pending
- 1999-08-20 HR HR20010206A patent/HRP20010206A2/hr not_active Application Discontinuation
- 1999-08-20 KR KR1020017002021A patent/KR20010085402A/ko not_active Ceased
- 1999-08-20 PL PL99356984A patent/PL356984A1/xx unknown
2001
- 2001-01-19 NO NO20010309A patent/NO20010309L/no not_active Application Discontinuation
- 2001-01-30 ZA ZA200100831A patent/ZA200100831B/en unknown
- 2001-02-16 IS IS5846A patent/IS5846A/is unknown
- 2001-03-16 LV LVP-01-45A patent/LV12732B/en unknown
- 2001-03-19 BG BG105362A patent/BG105362A/xx unknown
- 2001-03-19 LT LT2001024A patent/LT4904B/lt unknown

Also Published As

Publication number	Publication date
BR9913374A (pt)	2001-05-15
SI20746A (sl)	2002-06-30
LV12732A (en)	2001-10-20
EP1105120B1 (de)	2005-03-23
WO2000020358A3 (en)	2000-11-16
EA200100255A1 (ru)	2002-02-28
LV12732B (en)	2002-03-20
LT2001024A (en)	2001-11-26
EE200100102A (et)	2002-06-17
ES2237966T3 (es)	2005-08-01
WO2000020358B1 (en)	2001-01-04
CA2341346A1 (en)	2000-04-13
CZ2001523A3 (cs)	2002-05-15
IL141396A0 (en)	2002-03-10
SK2262001A3 (en)	2002-12-03
PL356984A1 (en)	2004-07-12
JP2002535244A (ja)	2002-10-22
TR200100631T2 (tr)	2002-08-21
DE69924387D1 (de)	2005-04-28
OA11599A (en)	2004-08-23
IS5846A (is)	2001-02-16
AP2001002053A0 (en)	2001-03-31
HRP20010206A2 (en)	2004-02-29
HUP0103622A2 (hu)	2002-04-29
CN1379666A (zh)	2002-11-13
AU759310B2 (en)	2003-04-10
EP1105120A4 (de)	2001-12-19
NO20010309D0 (no)	2001-01-19
YU13701A (sh)	2005-06-10
ID29244A (id)	2001-08-16
AU2470900A (en)	2000-04-26
NZ509252A (en)	2004-05-28
GEP20043315B (en)	2004-02-10
WO2000020358A2 (en)	2000-04-13
ATE291423T1 (de)	2005-04-15
LT4904B (lt)	2002-04-25
ZA200100831B (en)	2002-08-22
NO20010309L (no)	2001-04-11
HUP0103622A3 (en)	2003-01-28
KR20010085402A (ko)	2001-09-07
EP1105120A2 (de)	2001-06-13

Publication	Publication Date	Title
BG105362A (en)	2001-12-31	NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION
LV12631A (en)	2001-03-20	Non-peptide gnrh agents
MXPA03001320A (es)	2003-08-21	Agentes no peptidicos de la gnrh, composiciones farmaceuticas y procedimientos para su uso.
MX9804850A (es)	1998-09-30	Antagonistas de hormona liberadora de gonadotropina.
DE69620241D1 (de)	2002-05-02	Gonadotropin releasing hormon- antagonisten
NZ325060A (en)	2000-02-28	Non peptide indole derivative and their use as antagonists of gonadotropin releasing hormone
FI925652A0 (fi)	1992-12-11	Foerfarande och sammansaettningar foer foerhindrande av befruktning och behandling av benigna gynekologiska stoerningar
WO2002098363A3 (en)	2003-03-20	NON-PEPTIDE GnRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM
CA2467222A1 (en)	2003-05-22	Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
EP0368388A3 (de)	1991-07-17	3-Piperidinyl-1,2-benzisoxazole
MXPA02010066A (es)	2003-06-04	Estratrienos sustituidos en 8beta-hidrocarbilo para uso como estrogenos selectivos.
MXPA03005741A (es)	2003-09-05	Metodos y formulaciones para el tratamiento de disfuncion sexual femenina.
PE55998A1 (es)	1998-10-01	Derivados 19-nor-pregneno substituidos
EP0938317A4 (de)	2000-08-23	Zusammmensetzungen und verfahren zur verminderung von atmungsdepressionen
MXPA02011524A (es)	2004-09-10	Nuevas formas de cuerpo solido de mesoprogestina, 11b-[4e-(hidroxiiminometil)-fenil]-17alfa-metoximetil-17- ??-metoxi-estra-4,9-dien-3-ona.
Leihy et al.	2001	Virilization of the urogenital sinus of the tammar wallaby is not unique to 5α-androstane-3α, 17β-diol
UA74388C2 (uk)	2005-12-15	Фармацевтичні композиції тизоксаніду і нітазоксаніду
IL156811A0 (en)	2004-02-08	Bisaryl derivatives and pharmaceutical compositions containing the same
RO115802B1 (ro)	2000-06-30	Derivaţi ai acidului pirazol dihidrobenzofuranil propenoic, intermediar pentru prepararea acestora, compoziţii farmaceutice ale acestora şi metodă de tratament
IL147927A0 (en)	2002-08-14	Steroids, their preparation, pharmaceutical compositions thereof and uses of the compounds
PL310357A1 (en)	1995-12-11	Fecundation preventing or inhibiting method
GB9929582D0 (en)	2000-02-09	Chemical compounds
AU5278799A (en)	2000-01-10	Unsaturated 14,15-cyclopropanoandrostanes, method for the production thereof andpharmaceutical preparations containing said compounds
Kincl et al.	1967	The effect of intrasplenic ovarian autografts on luteinization in rats treated neonatally with steroid hormones
IT1253008B (it)	1995-07-10	Derivati dell'eserolina ad attivita' anticolinesterasica,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono